UMC119-06-05
AssetAlso UMC119-01, UMC-119-06, UMSC-01, Solizmestrocel
Allogeneic umbilical cord mesenchymal stem cells administered to mitigate frailty syndrome.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Inflammation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Pathologic processes
Phase 1, Active not recruiting, NCT06501066, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Aging relevance3
Every asset’s record: target, stage, trials and the evidence behind it.